stockrowMirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
Follow MIRM
Alert me
Mirum Pharmaceuticals, Inc. (MIRM) Revenue
Mirum Pharmaceuticals, Inc.'s revenue for fiscal 2025 was $521.3M, up 54.7% from $336.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was $670.8M. Over the past ten years it has ranged from $19.1M (fiscal 2021) to $521.3M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 4 consecutive fiscal years. Mirum Pharmaceuticals, Inc. ranks 35th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $521.3M | 54.74% |
| FY2024 | $336.9M | 80.76% |
| FY2023 | $186.4M | 141.85% |
| FY2022 | $77.1M | 302.66% |
| FY2021 | $19.1M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $185.7M | 5.38% |
| Jun 2026 | $176.2M | 10.23% |
| Mar 2026 | $159.9M | 7.35% |
| Dec 2025 | $148.9M | 11.97% |
| 18 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $1.2B |
| IONS Ionis Pharmaceuticals, Inc. compare | $874.1M |
| MIRM Mirum Pharmaceuticals, Inc. | $670.8M |
| LGND Ligand Pharmaceuticals Incorporated compare | $253.8M |
| CGON CG Oncology, Inc. compare | $6.2M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| IMVT Immunovant, Inc. compare | — |
| ORKA Oruka Therapeutics, Inc. compare | — |
| KOD Kodiak Sciences Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on MIRM
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement